Scientists & Thinkers: ANDREW VON ESCHENBACH

Jacobson, Michael
May 2006
Time International (South Pacific Edition);5/8/2006, Issue 18, p62
The article presents information on Andrew C. von Eschenbach, head of the U.S. National Cancer Institute. von Eschenbach has been a longtime friend of U.S. president, George W. Bush. Although his career has been focused on curing disease, von Eschenbach has a unique opportunity to prevent disease by bolstering the Food and Drug Administration's food side. He could make a signal contribution to the public's health, if he spends as much energy on foods as he is expected to spend on drugs.


Related Articles

  • FDA Acting Commissioner von Eschenbach has background in cancer research. Reynolds, Bob // Pharmacy Today;Nov2005, Vol. 11 Issue 11, p38 

    The article reports that U.S. President George W. Bush has appointed Andrew C. von Eschenbach as the acting commissioner of the U.S. Food and Drug Administration. Earlier, he was working with the U.S. National Cancer Institute as the director. He is the great advocate of collaborative team...

  • New Concerns Dog the FDA. Wallis, Claudia; Roston, Eric // Time;10/10/2005, Vol. 166 Issue 15, p14 

    This article focuses on U.S. President George W. Bush's selection of Dr. Andrew von Eschenbach as interim chief of the Food and Drug Administration (FDA). Eschenbach, who has no regulatory experience but is a close friend of the Bush family, was appointed to replace Lester Crawford, who left...

  • FDA Nomination.  // Pharmaceutical Executive;Apr2006, Vol. 26 Issue 4, p23 

    The article reports on the nomination of Andrew von Eschenbach as chairman of the Food and Drug Administration by President George W. Bush in the U.S. The administration has been searching for the right person with medical and research credentials, knowledgeable about the regulatory issues and...

  • The War on Cancer. Moss, Ralph W. // Townsend Letter;Jun2006, Issue 275, p33 

    The article questions the feasibility of National Cancer Institute director Andrew C. von Eschenbach's goal of eliminating the suffering and death due to cancer by 2015. There appears to be no explanation of how the goal could be realized. Further, the Administration that he serves, the one...

  • Bush Signs Bill Reauthorizing PDUFA. Greb, Erik // Pharmaceutical Technology;Nov2007, Vol. 31 Issue 11, p24 

    The article reports on the signing of Food and Drug Administration Amendments Act by U.S. President George W. Bush into law, thereby reauthorizing the Prescription Drug User Fee Act. The H.R. 3580 act increases drug-safety authority, encourages innovation and provides needed resources. According...

  • The FDA is no place for politics.  // Nature Structural & Molecular Biology;May2006, Vol. 13 Issue 5, p379 

    The article calls for the end of political interventions in the operations of the United States Food and Drug Administration (FDA). The FDA has been without a permanent administrator for much of the presidency of George W. Bush because of political maneuvers. Bush's nominee for the position,...

  • Bush nominates new FDA chief.  // Drug Topics;4/3/2006, Vol. 150 Issue 7, p8 

    The article reports that U.S. President George W. Bush nominates Food and Drug Administration (FDA) commissioner Andrew von Eschenbach to head the agency. Eschenbach, who also heads the National Cancer Institute, may face conflict-of-interest charges at his confirmation hearings. The Senate...

  • The FDA is Treading Water Until a True Leader Arrives. Thiel, Karl // BioWorld Today;3/31/2008, Vol. 19 Issue 62, p1 

    The author comments on the need for a true leader of the U.S. Food and Drug Administration (FDA). The author relates the reasons given by the FDA for the failure to meet many Prescription Drug User Fee Act goals. The author questions the budget request made by the FDA. The author criticizes...

  • As I See It. Dickinson, James G. // Medical Marketing & Media;May2006, Vol. 41 Issue 5, p16 

    The author comments on President George W. Bush's nomination of Andrew von Eschenbach to be the permanent commissioner of the U.S. Food and Drug Administration (FDA). According to the author, the opposition against von Eschenbach's nomination is a result of Bush's blocking of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics